GlobeNewswire Press Releases - EIN Presswire - Press Release Distribution Service

Published on April 23, 2026 - 06:00 GMT

Orion Pharma on aloittanut TEADCO Faasi 1b/2 -tutkimuksen ODM-212-molekyylillä yhdessä vakiintuneiden hoitojen kanssa potilailla, ...

ORION OYJ LEHDISTÖTIEDOTE 23.4.2026 KLO 9.00 Orion Pharma on aloittanut TEADCO Faasi 1b/2 -tutkimuksen ODM-212-molekyylillä yhdessä vakiintuneiden hoitojen kanssa potilailla, joilla on tiettyjä pitkälle edenneitä kiinteitä …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on April 23, 2026 - 05:47 GMT

Lloyd’s syndicate results above average for 2025 with wide disparity at individual syndicate level

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- 2025 Results Syndicate Research Limited (SRL) stated that the weighted average result1 as a % of Net Premium Earned (NPE), excluding Funds In Syndicate investment returns (FIS2), for those Lloyd’s of London (Lloyd …

Distribution channels: Business & Economy ...

Published on April 23, 2026 - 05:35 GMT

Moomoo launches API Skills facility, a first in Australia and New Zealand

SYDNEY, April 23, 2026 (GLOBE NEWSWIRE) -- Global trading platform moomoo has launched Moomoo API Skills, the first professional-grade facility offered in the local market by a trading platform, that bridges the gap between personal AI agents and live …

Distribution channels:

Published on April 23, 2026 - 05:30 GMT

Press Release: Q1 2026: double-digit sales and business EPS growth

Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER1 and business earnings per share (EPS)2 of €1.88 Pharma launches sales increased by 49.6%, reaching €1.2 billion, driven primarily by Ayvakit, …

Distribution channels:

Published on April 23, 2026 - 05:30 GMT

Eramet : croissance soutenue du chiffre d’affaires au 1er trimestre 2026 portée par une bonne performance opérationnelle

Paris, le 23 avril 2026, 7h30 COMMUNIQUE DE PRESSE Eramet : croissance soutenue du chiffre d’affaires au 1er trimestre 2026 portée par une bonne performance opérationnelle Taux de fréquence des accidents du Groupe en forte amélioration sur le trimestre, …

Distribution channels:

Published on April 23, 2026 - 05:30 GMT

Eramet: strong turnover momentum in Q1 2026 driven by a solid operational performance

Paris, 23 April 2026, 7:30 a.m. PRESS RELEASE Eramet: strong turnover momentum in Q1 2026 driven by a solid operational performance Strong quarterly improvement in the Group accident frequency rate, however with a fatal accident to report in January …

Distribution channels:

Published on April 23, 2026 - 05:30 GMT

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 ...

Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that …

Distribution channels:

Published on April 23, 2026 - 05:30 GMT

Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA

T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA Paris, le 23 avril 2026 Ventes du T1 en progression de 13,6 % à TCC1 et BNPA2 des activités de 1,88 euro Les ventes des nouveaux lancements Pharma progressent de 49,6 %, atteignant 1,2 …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on April 23, 2026 - 05:30 GMT

Destinus achieves key milestone in next-generation long-range strike capability

AMSTERDAM, April 23, 2026 (GLOBE NEWSWIRE) -- Destinus announces the successful completion of a landmark flight test of its precision deep-strike system, Ruta Block 2. The test validates the next-generation of launch architecture and confirms the …

Distribution channels: Aviation & Aerospace Industry, Media, Advertising & PR ...

Published on April 23, 2026 - 05:30 GMT

OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au ...

Nantes, France, 23 avril 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et immuno-inflammation,annonce aujourd’ …

Distribution channels: Media, Advertising & PR, Technology ...

Published on April 23, 2026 - 05:01 GMT

Teck Reports Unaudited First Quarter Results for 2026

VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited first quarter results for 2026. “We delivered a very strong start to 2026, underpinned by …

Distribution channels: Business & Economy, Mining Industry ...